AARS1 and major depressive disorder: We identified six reports investigating the genetic variants of noradrenergic receptors or proteins expressed within the noradrenergic synthetic pathway, and their relationship to either symptoms of MDD and schizophrenia or the side effects of treatment with agents that have activity at α-ARs.